Saturday 17 October 2026
Export LMRI’s income statement to Excel — free account
Lumexa Imaging Holdings, Inc.
LMRI Healthcare Medical Devices
Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024. In the quarter to June 2026, revenue grew 7.82%, EPS grew 127.1% and free cash flow grew 257.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.64
0.14
−1.30%
Follow LMRI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 15.81 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 19.45 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 4,335 | 5,019 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.22 | 0.20 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 936 | 949 | 1,023 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 10.57 | 10.15 | 15.40 | |||||
| EBT | — | — | — | — | — | — | — | (119) | (79) | (32) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (12.74) | (8.35) | (3.15) | |||||
| Net income | — | — | — | — | — | — | — | (122) | (94) | (47) | |||||
| Depreciation | — | — | — | — | — | — | — | 97 | 63 | 62 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 13.48 | 13.66 | 14.41 | ||||
| Earnings | — | — | — | — | — | — | — | (1.76) | (1.35) | (0.66) | |||||
| Cash flow | — | — | — | — | — | — | — | 0.54 | 0.59 | 0.24 | |||||
| Capex | — | — | — | — | — | — | — | (0.35) | (0.39) | (0.29) | |||||
| Free cash flow | — | — | — | — | — | — | — | 0.19 | 0.19 | (0.05) | |||||
| Book value | — | — | — | — | — | — | — | 0.00 | 2.33 | 8.26 | |||||
| Shares, m | — | — | — | — | — | — | — | 69 | 69 | 71 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | 7.97 | 7.97 | 2.24 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | 246.79 | 246.79 | (293.46) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 38 | 41 | 17 | ||||
| Capex | — | — | — | — | — | — | — | (24) | (27) | (21) | |||||
| Free cash flow | — | — | — | — | — | — | — | 14 | 13 | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | (1) | 48 | ||||
| Total debt | — | — | — | — | — | — | — | — | 1,217 | 865 | |||||
| Net debt | — | — | — | — | — | — | — | — | 1,191 | 807 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 162 | 586 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (11.27) | (2.74) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 2.55 | 4.39 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 0.00 | (12.60) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Lumexa Imaging Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care, Inc. | $1.2B | — (loss-making) | — (loss-making) | +5.77% (above 0%: growing) | n/m | −146.34% (below 0%: shrinking) | 56.87% | (5.42%) | Compare |
| IRMD iRadimed Corporation | $1.1B | 48.5× | 48.7× | +0.28% (above 0%: growing) | −8.89% (below 0%: shrinking) | +11.66% (above 0%: growing) | 74.07% | 31.23% | Compare |
| ENOV Enovis Corporation | $1.1B | — (loss-making) | 195× | +3.23% (above 0%: growing) | n/m | +815.79% (above 0%: growing) | 61.64% | 2.99% | Compare |
| AORT Artivion, Inc. | $1.1B | — (loss-making) | 142× | +11.32% (above 0%: growing) | n/m | −202.47% (below 0%: shrinking) | 64.03% | (6.65%) | Compare |
| CBLL CeriBell, Inc. | $1.1B | — (loss-making) | — (loss-making) | +32.54% (above 0%: growing) | n/m | −68.63% (below 0%: shrinking) | 92.32% | (71.11%) | Compare |
| IART Integra LifeSciences Holdings Corporation | $1.1B | — (loss-making) | 26.1× | +0.76% (above 0%: growing) | n/m | +193.48% (above 0%: growing) | 52.47% | 4.61% | Compare |
| LMRI Lumexa Imaging Holdings, Inc. | $1.0B | — (loss-making) | 14.2× | +7.82% (above 0%: growing) | n/m | +257.54% (above 0%: growing) | 14.72% | 8.72% | |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | — (loss-making) | — (loss-making) | +19.34% (above 0%: growing) | n/m | −24.43% (below 0%: shrinking) | 66.01% | (28.98%) | Compare |
| QDEL QuidelOrtho Corporation | $953.9M | — (loss-making) | — (loss-making) | +2.77% (above 0%: growing) | n/m | −61.45% (below 0%: shrinking) | 43.26% | (3.46%) | Compare |
| Median of peers | $1.1B | — | 95.4× | +4.50% | — | −42.94% | 62.84% | (4.44%) |
Lumexa Imaging Holdings, Inc. (LMRI) key facts
- Strength: Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024.
- Lumexa Imaging Holdings, Inc. (LMRI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LMRI traded at $10.64, a market capitalization of $1.0 billion.
- Return on equity was −12.6% and debt-to-equity 1.42.
- Its Altman Z-score is 0.96 (distress zone) for fiscal 2025.